Objective: to review an update of autoimmune hepatitis in children, based on classification, diagnostic and therapeutic criteria.
Introduction
Autoimmune hepatitis is a continuous inflammatory disease of the liver, with variable beginning and duration, caused by unknown factors. It constitutes a syndrome characterized by the presence of clinical, biochemical, serologic, and histological elements, which suggest immunologic reaction against antigens of the host, and lead to irreversible cellular damage. It usually affects young, female patients, and it is characterized by the presence of hypergammaglobulinemia, organ nonspecific circling autoantibodies, and histological alterations, with lymphoplasmocytic inflammatory infiltrate, interface hepatitis, and presence, most of the times, of rosetteforming hepatocytes. The therapeutic response to corticosteroids occurs in 80% of the cases, and then clinical, laboratory, and therapeutic remission takes place. An association with other extrahepatic autoimmune diseases may occur (autoimmune thyroiditis, arthritis, hemolytic anemia, and glomerulopathies). 1 In childhood, it is considered a rare entity, corresponding to about 10% of the patients with chronic liver disease. [2] [3] [4] [5] [6] In Brazil, it is also considered a rare disease, and affects approximately 5 to 10% of the hepatic diseases in the main gastroenterology services in the country. 7 According to data from the Liver Unit and the Children's Institute of Hospital de Clínicas, School of Medicine, Universidade de São Paulo, autoimmune hepatitis corresponds to less than 5% and less than 2% of the adult and pediatric patients, respectively, in the wait for hepatic transplantation (personal communication). 7 The classification of autoimmune hepatitis can be based on clinical, laboratory, histological, genetic, and pathogenetic findings. However, the classification most commonly accepted by authors 8 is based on the presence of organ-nonspecific autoantibodies, according to the description that follows.
Type 1 -This type of autoimmune hepatitis is present when there is positivity to the antimuscle antibody, particularly to the anti-actin antibody, associated or not with antinuclear antibodies. Other antibodies may be found, such as those directed against soluble liver antigens (against cytokeratin 8 and 18), which may be present in approximately 30% of the cases. 9 Besides these antibodies against liver and pancreas antigens, there may be nuclear envelope proteins (laminins A and C) 9 against antineutrophil cytoplasmic antibodies, and anticytoplasmic antibodies against cytoplasmic components of neutrophils. 10, 11 Type 2 -This type presents positivity to anti-liverkidney microsomal antibodies type 1. This type usually starts in childhood, and the antibodies are directed against an IID6 antigen of cytochrome P450 isoform (CYP2D6). Indirect immunofluorescence stains hepatocytes and renal proximal tubules; because of this, this type of hepatitis is also denominated anti-liver-kidney microsome antibodies type 1. Anti-CYP2D6 are found in 95 to 100% of the patients with autoimmune hepatitis type 2. 12,13 Anti-liver cytosol antibodies may also be found, and, occasionally, this may be the only antibody present in this type of autoimmune hepatitis. 14 Through the indirect immunofluorescence technique, this antibody is characterized by fluorescence of hepatocytes in the periportal region, and not in the centrolobular perivein. 14, 15 These two types of autoimmune hepatitis are also different concerning the genetic susceptibility related to autoimmune hepatitis. So, in Europe and in the United States, studies showed association with the HLA-A1-B8-DR3 molecule, and, secondarily, with DR4 in autoimmune hepatitis type 1. 16 In Japan, it was associated with the HLA-DR4 molecule. 17 In Argentina, Faimboin et al., 18 studying children with autoimmune hepatitis, observed association of the disease with the antigens HLA-DR13 and DQ6. In Brazil, Bittencourt et al. 19 observed association, particularly in children, of autoimmune hepatitis type 1 with HLA-DR13 and DQ6, and, secondarily, with HLA-DR3, similarly to the findings in Argentina. On the other hand, the same authors found association of autoimmune hepatitis with HLA-DR7 and DQ2, and, secondarily, with DR3 in patients with autoimmune hepatitis type 2, which is a new fact in the literature. 19 In a survey performed together with the Gastroenterology Department and the Pediatric Hepatology Unit, at Instituto da Criança, Hospital de Clínicas, Medical School, Universidade de São Paulo, 225 patients, including children, adolescents and adults with diagnosis of autoimmune hepatitis were classified according to the presence of types of organ-nonspecific autoantibodies:
Clinical status and laboratory exams
Most times, autoimmune hepatitis presents symptoms compatible with acute hepatitis. A study carried out in 111 children and teenagers with autoimmune hepatitis at Instituto da Criança Prof. Pedro de Alcântara showed an abrupt beginning of the disease in 89% of cases, an insidious beginning in 19%, associated jaundice, choluria, fever, asthenia, anorexia, emaciation, and increased abdominal volume. In some cases, the presentation form is fulminant; this usually occurs in type 2 autoimmune hepatitis. 20 The course of the disease may be persistent or recurrent. There are no differences regarding symptoms in the different types of autoimmune hepatitis. However, type 2 is more frequent in earlier ages than type 1. Some cases may manifest sings of hepatic decompensation (already advanced) since the beginning, such as ascites, gastrointestinal bleeding, hepatic encephalopathy, and even coma. Variable degrees of portal hypertension and history of upper gastrointestinal bleeding may also occur since the beginning, and they depend on the duration of the disease. Asymptomatic patients, diagnosed accidentally due to alterations in biochemical exams of the hepatic function, are rare. Hepatomegaly is present in 90% of the cases, and splenomegaly, in 60%. Associated extrahepatic manifestations may be present, such as acne, inflammatory papules, pregnancy striae, Weber paniculitis, arthritis, arthralgia, albuminuria, hematuria, glomerulonephritis, renal tubular acidosis, intestinal inflammatory disease, pleural effusions, pleurisy, pulmonary arteriovenous anastomoses, fibrosing alveolitis, polyarteritis nodosa, Cushingoid facies, gynecomastia in boys, amenorrhea, thyroiditis, diabetes mellitus type 1, autoimmune hemolytic anemia, iridocyclitis. 21 The appearance of hepatocellular carcinoma constitutes a rare complication. 22 The most characteristic laboratory findings are increase in the transaminases, which may reach levels compatible with an acute hepatitis (>1,000 U/L), and hypergammaglobulinemia. The levels of gammaglutamyltranspeptidase and alkaline phosphatase may be also high, but they are lower than transaminases. Bilirubin levels, due to direct fraction, are usually increased, except for the insidious and prolonged forms, in which they may be normal. Albumin levels are usually decreased, and prothrombin time is prolonged. Gammaglobulinemia is increased in most patients, with levels superior to 2 g/dL, and much higher values are observed in type 1 when compared to type 2 autoimmune hepatitis. IgG values are almost always elevated, and they are much higher in type 1 autoimmune hepatitis; low levels of IgA are found particularly in type 2 autoimmune hepatitis, and these values are much higher than the level of IgM in type 1 autoimmune hepatitis. Complement concentrations, particularly C4, may be low, with levels much lower in type 2 when compared to type 1 autoimmune hepatitis; C3 may be low in both types. Anemia may be discrete, in general microcytic-hypochromic, except when it is associated with hemolytic process. Leukopenia and There is no criterion totally established for the diagnosis of autoimmune hepatitis yet. It is based on the presence of a clinical status compatible with hepatitis, variable evolution, with or without other extrahepatic manifestations, absence of infection markers (such as hepatitis A, B, or C viruses), increase in transaminases, hypergammaglobulinemia, increased levels of immunoglobulins, and presence of organnonspecific autoantibodies. Variable patterns of autoantibodies and clinical manifestations lead to the hypothesis that this disease is a heterogeneous syndrome, with several possible etiologies. In some cases, autoimmune hepatitis is suspected even when no immunologic markers or hypergammaglobulinemia are found, and when there is a good response to corticosteroids. In 1993, an international group led by Johnson 24 elaborated criteria for an improved systematization and characterization of the disease in order to make its diagnosis become easier. These criteria, though, were revised by this group in 1999. 25 A score system was proposed aiming at creating a set of descriptive criteria for difficult cases or when there was the need for a more objective evaluation. The diagnosis of autoimmune hepatitis should be considered in spite of the score proposed to any patients, independently on the gender, presenting either acute or chronic liver disease, and abnormal hepatic biochemical test in the absence of signs and symptoms of any other hepatic disease already studied, especially if there is history of autoimmune diseases in the patient or in his/her first relatives.
The score system was proposed aiming at creating a set of descriptive criteria for difficult cases, or when there was the need for a more objective evaluation. 2. Wilson disease -This disease should be considered in all cases of hepatic disease with acute or chronic onset and negative serological markers. In childhood, neurological symptoms are not frequent, and liver disease is preponderant; Kayser-Fleischer ring is almost always absent.
Differential diagnosis 1. Acute hepatitis -This diagnosis is excluded when there is negativity to IgM-HAV (hepatitis A virus) and antiHBc IgM (type B), PCR-HCV (type C), IgM (cytomegalovirus), VCA-IgM-VEB (Epstein Barr virus).

Parameters Score
Sex
Alpha-1 antitrypsin deficiency -This protein should
be assessed in any case of chronic liver disease. Low levels suggest alpha-1 antitrypsin deficiency, but the golden standard for the diagnosis is the performance of phenotype through isoelectric focalization or polymerase chain reaction. PiZZ phenotype defines the deficiency, and this may lead or not to hepatic cirrhosis.
Primary sclerosing cholangitis -
This disease may start still in the neonatal period. 31 In childhood, few patients present symptoms of itching, arthralgia, or complications of the disease. The suspicion is present when there is hepatosplenomegaly or hepatomegaly, with canalicular enzymes usually significantly elevated (gammaglutamyltranspeptidase and alkaline phosphatase); it may be associated with inflammatory bowel disease. The definitive diagnosis is carried out with cholangiography showing intra and/or extrahepatic alterations in the biliary tree. There are also mixed forms of autoimmune and primary sclerosing cholangitis, whose diagnosis is frequently difficult. In patients presenting autoimmune hepatitis, positive FAN, and positive anti-actin antibody, the performance of retrograde cholangiography is sometimes of paramount importance, particularly in cases with symptoms suggestive of autoimmune hepatitis and that do no respond well to associated corticotherapy or to azathioprine, even with canalicular enzymes not significantly altered.
Chronic hepatitis type C -
The etiologic relationship between hepatitis C virus and autoimmune hepatitis, particularly of type 2 (anti-liver-kidney microsome antibodies type 1) has been intensely studied. 26 About onethird of patients infected with hepatitis C virus present several immunologic alterations, with the presence of autoantibodies, particularly anti-liver-kidney microsome antibodies type 1, but also antimuscle antibodies and FAN. It seems that the analogy between autoimmune hepatitis and type C chronic hepatitis is related only to the autoreactivity profile, with the presence of autoantibodies. Data suggest that cases with FAN and/or antimuscle autoantibodies present more activity of the disease.
Treatment
The efficacy of the treatment with immunosuppressants is assessed by the patient's ability to induce complete remission, as well as to maintain it after the suspension of the drug; the main objective is the definitive control of the disease.
In 1993, the International Autoimmune Hepatitis Group 24 established a set of criteria to uniformly define the therapeutic response, considering that several schemes were efficacious; these schemes were reviewed in 1999, 25 only in order to get simplified. They would serve to evaluate any therapeutic regimen used.
Complete response
The complete response consists of one or both of the following items:
-Accentuated improvement of symptoms and normalization of all the hepatic function tests (aspartate and alanine aminotransferases), bilirubins, and immunoglobulins) in the 1st year counting from the beginning of the treatment and being maintained by at least 6 months during therapy, or minimal inflammatory activity showed by hepatic biopsy at any moment of the treatment.
-Accentuated improvement of the symptoms and decrease of at least 50% in all hepatic function tests in the 1st month of treatment, with aspartate and alanine aminotransferase levels decreasing until reaching less than two times the superior limit of normality within 6 months, and during any reductions, until reaching the ideal therapeutics, or minimal inflammatory activity showed by hepatic biopsy within 1 year.
Relapse
It consists of one or both of the following items: -Increase in the levels of serum aspartate and alanine aminotransferases higher than two times the superior limit of normality, or inflammatory activity showed by hepatic biopsy, with or without the reappearance of symptoms and after the complete response, as defined previously.
-Reappearance of the symptoms, requiring increase (or reintroduction) of immunosuppressants, accompanied by any increase in aspartate and alanine aminotransferases after previous complete response.
Currently, the survival rate in treated pediatric patients is over 90% 10 years after the diagnosis, and the rate of remission induced by therapy with immunosuppressants is approximately 80%. About 50% of the patients remain in remission or present only a mild form of the disease when the medication is withdrawn. 27 The monitoring of the therapeutic response is important to assess the patient's and his/her relatives' adhesion to drugs and procedures prescribed along the treatment. Treatment consists of giving prednisone alone or associated with azathioprine.
In childhood, two schemes may be used 27 : 1. Initial: a) Sole drug: prednisone at 1-2 mg/kg/day (maximal dose 60 mg/day). b) Associated therapy: prednisone at 1-2 mg/kg/ day, and azathioprine at 1.5-2 mg/kg/day.
Maintenance:
a) Sole drug: prednisone at 1 mg/kg/day, or azathioprine at 1.5-2 mg/kg/day. b) Associated therapy: prednisone at 0.1-0. 25 mg/kg/day, and azathioprine at 1.5-2 mg/kg/day. The monitoring should be performed every 6-8 weeks during the first 6 months of treatment; posteriorly, it should happen every 3-6 months, until 2 years have passed since the beginning of treatment. The reduction in corticosteroid is carried out at each medical appointment, until the maintenance dose is achieved. At each visit, clinical evaluation is performed, as well as the following laboratory exams: complete hemogram, platelet count, coagulogram (with dosages of prothrombin time, activated partial thromboplastin time, and thromboplastin time), serum determination of aminotransferases (aspartate and alanine), gammaglutamyltranspeptidase, alkaline phosphatase, total and fraction protein, and bilirubin electrophoresis. Hepatic biopsies are performed whenever possible (depending on the coagulogram values) before the beginning and 2 years after the treatment, provided that the patient has responded to the treatment. Patients that do not respond adequately to the treatment should undergo percutaneous or endoscopic retrograde cholangiography, and the performance of another biopsy is not recommended, since it does not help in the treatment. The suspension of drugs rarely occurs, and when it does, it is usually in type 2. Some patients remain in remission for months and years; however, they should be monitored every 6 months. The first sign of relapse is usually loss of appetite, anorexia, myalgia, tiredness, and/ or alterations in the hepatic function tests. Most children are asymptomatic when they relapse. The handling of relapses depends on the severity of the case. Sometimes, initial doses are given, but usually corticosteroid levels are low. Patients that relapse should receive drugs during the whole life, usually associated. All patients with type 3 autoimmune hepatitis relapse after drug withdrawal. In the literature, the relapse rate after the suspension of drugs in adults ranges from 50 to 87% of the cases. [27] [28] [29] This confirms the impossibility of interrupting the treatment. Studies carried out at the Clínica Mayo show a histological aggravation in relation to the number of relapses. 29 In cases of therapeutic failure, with evolution to hepatic insufficiency, the hepatic transplantation should be considered. The recurrence of the disease after surgery is extremely rare, and autoantibodies disappear completely. 30 
